# Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease

> **NCT03437720** · PHASE2 · WITHDRAWN · sponsor: **Sanofi**

## Conditions studied

- Non-alcoholic Steatohepatitis
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** SAR425899
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03437720
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-23
- **Primary completion:** 2021-08-25
- **Final completion:** 2021-08-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to cancel TRIAL, not related to safety concern.
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437720, "Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03437720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*